Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes
|
|
- Julie Taylor
- 5 years ago
- Views:
Transcription
1 585298DVR / Diabetes & Vascular Disease ResearchSjöström et al. research-article2015 Original Article Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes Diabetes & Vascular Disease Research 2015, Vol. 12(5) Astra Zeneca 2015 Reprints and permissions: sagepub.co.uk/journalspermissions.nav DOI: / dvr.sagepub.com C David Sjöström 1, Peter Johansson 1, Agata Ptaszynska 2, James List 2,3 and Eva Johnsson 1 Abstract The effect of dapagliflozin on blood pressure was evaluated in non-hypertensive (<140 mm Hg) and hypertensive ( 140 mm Hg) patients with type 2 diabetes mellitus. Data were pooled from 13 placebo-controlled studies. Patients received dapagliflozin 10 mg/day (n = 2360) or placebo (n = 2295) for up to 24 weeks. Dapagliflozin was associated with placebo-subtracted changes from baseline in systolic and diastolic blood pressures of 3.6 and 1.2 mm Hg, respectively, in hypertensive patients and 2.6 and 1.2 mm Hg, respectively, in non-hypertensive patients. At 24 weeks, a similar proportion of patients experienced measured orthostatic reactions with dapagliflozin versus placebo in hypertensive (6.1% and 6.6%, respectively) and non-hypertensive (4.0% and 4.2%) patients. No clinically relevant difference was observed between dapagliflozin and placebo in heart rate. In conclusion, dapagliflozin 10 mg induces a modest reduction in blood pressure compared with placebo in patients with diabetes with a low risk of orthostatic reactions, regardless of baseline blood pressure. Keywords Dapagliflozin, sodium-glucose co-transporter 2 inhibitor, hypertension, blood pressure, type 2 diabetes Introduction Patients with diabetes are more than twice as likely as those without diabetes to develop hypertension. 1 As with non-diabetic patients, hypertension predisposes patients with diabetes to an increased risk of cardiovascular disease. However, this risk increases significantly in patients with both diabetes and elevated blood pressure (BP) compared with normotensive patients. 1 3 Hypertension is a multifactorial disease, and the causes leading to an increase in incidence in the diabetic population are complex. It is estimated that close to 90% of the patients with type 2 diabetes mellitus (T2DM) are overweight or obese. 4 Because weight gain is associated with an accompanying increase in BP, 5 this may, in part, contribute to the higher incidence of hypertension in this population. Angiotensin II, a vasoconstrictor with salt-retaining activity, is a component of the renin-angiotensin-aldosterone system (RAAS). Activation of RAAS, resulting in an increase in insulin resistance, has also been implicated as a potential causal factor in the development of hypertension in T2DM. 6,7 In addition, it has been proposed that during periods of hyperglycaemia, insulin itself may have a sodium-retentive effect that may be sufficient to promote or exacerbate hypertension. 8 Reducing BP in patients with diabetes is associated with a reduced risk of macrovascular disease. 9,10 The European Society of Hypertension and the European Society of Cardiology recommend initiating treatment in patients with a systolic blood pressure (SBP) of 140 mm Hg or a diastolic blood pressure (DBP) of 90 mm Hg. 11 In addition, the American Diabetes Association and European Society of Cardiology/European Association for the Study of Diabetes recommend achieving an SBP of <140 mm Hg in patients with diabetes, although a lower goal (<130 mm Hg) may be appropriate in younger patients or those with kidney disease. 12,13 Despite those threshold-driven recommendations, guidelines recognise a continuous, independent relationship of seated BP, ranging from high to relatively low ( /70 75 mm Hg), with the risk of cardiovascular events AstraZeneca, Mölndal, Sweden 2 Bristol-Myers Squibb, Princeton, NJ, USA 3 Formerly Bristol-Myers Squibb, Princeton, NJ, USA Corresponding author: C David Sjöström, AstraZeneca, Pepparedsleden 1, Mölndal SE , Sweden. david.sjostrom1@astrazeneca.com
2 Sjöström et al. 353 CVD NCT CVD and Hypertension NCT Add-on to SITA NCT Add-on to INS NCT Add-on to INS NCT Add-on to SU NCT Add-on to TZD NCT Add-on MET (BW) NCT Add-on to MET XR NCT Add-on to MET NCT MONO - Japan NCT MONO NCT MONO NCT Meta-analysis data indicate similar risk reductions associated with BP lowering regardless of pre-treatment BP or cardiovascular risk. 14 Dapagliflozin is a highly selective inhibitor of sodiumglucose co-transporter 2 (SGLT2) that improves glycaemic control and reduces body weight in an insulin-independent manner in patients with T2DM through a reduction in renal glucose reabsorption and accompanying urinary glucose excretion. 15 Dapagliflozin also reduces BP in patients with T2DM The BP-lowering effect may partly be explained by osmotic diuresis and possibly an altered sodium balance. 20 There is also a strong indication that the BP effect is also influenced by weight loss, 21 or rather a negative energy balance, as the full effect is visible before maximal weight loss has been attained. 22,23 The aim of this pooled analysis was to evaluate whether baseline BP would have any impact on the subsequent BP-lowering effect of dapagliflozin in patients with T2DM. Methods Study length (weeks) Figure 1. Studies included in the analyses. BW: body weight; CVD: cardiovascular disease; INS: insulin; MET: metformin; MONO: monotherapy; SITA: sitagliptin; SU: sulfonylurea; TZD: thiazolidinedione; XR: extended release. Data were pooled from 13 phase 2b/3 dapagliflozin placebo-controlled clinical studies (Figure 1). Each study was designed and performed in accordance with the ethical principles that have their origin in the Declaration of Helsinki and are consistent with the International Conference on Harmonisation/Good Clinical Practice, the applicable regulatory requirements and the AstraZeneca policy on bioethics. All patients provided informed consent. Patients with T2DM were randomised to receive dapagliflozin 10 mg/day (n = 2360) or placebo (n = 2295) as monotherapy or in combination with other antihyperglycaemic medications for up to 24 weeks. The primary objective of this analysis was to evaluate the effect of dapagliflozin 10 mg/day on BP in patients with T2DM and baseline SBP > 140 mm Hg (hypertensive) or baseline SBP 140 mm Hg (non-hypertensive). BP levels were used to define hypertension in this analysis regardless of the use of anti-hypertensive agents, and as such, there were patients in both groups with a medical diagnosis of hypertension. Baseline BP was determined by a single time point measurement performed in triplicate with the patient in a seated position. Heart rate and measured orthostatic reactions (defined as a decrease of >20 mm Hg in SBP or >10 mm Hg in DBP when transferring from a supine to standing position) were also measured. Additionally, any observed adverse events of orthostatic hypotension, as defined by the Medical Dictionary for Regulatory Activities, were recorded over the treatment period. The data were analysed using a linear model with factors for treatment, study and baseline SBP category, with the baseline measurement as a covariate. In addition to the abovementioned analyses in hypertensive and non-hypertensive patients, a sub-analysis of the non-hypertensive group only consisting of those patients with a pre-treatment SBP 120 mm Hg was performed in order to further characterise the safety profile of dapagliflozin in patients with very low BP. Results Patients Overall, 2294 patients receiving dapagliflozin and 2222 receiving placebo who had baseline BP measurements and at least one post-baseline BP measurement were included in these analyses. Patient demographics and baseline characteristics were generally balanced between dapagliflozin and placebo groups (Table 1). Hypertensive patients tended to be older, weigh more, have a longer duration of T2DM and to have a higher prevalence of pre-existing cardiovascular disease and/or hypertension than their normotensive counterparts. In addition, more patients with SBP > 140 mm Hg at baseline were being treated with BP-lowering medications in the dapagliflozin and placebo groups (91.5% and 91.1%, respectively), either because of a diagnosis of hypertension or other indications, compared with patients with baseline SBP 140 mm Hg (68.2% and 72.6%, respectively, Table 2). The use of specific anti-hypertensive treatments at baseline was balanced between dapagliflozin- and placebotreated patients; angiotensin-converting enzyme inhibitors and angiotensin receptor blockers were most commonly used. The proportion of patients on anti-hypertensive drugs remained stable over the 24-week treatment period in both groups (change 1%). BP Following initiation of treatment, SBP dropped in hypertensive patients in both dapagliflozin and placebo treatment groups over the first week and levelled off thereafter through
3 354 Diabetes & Vascular Disease Research 12(5) Table 1. Demographics and baseline characteristics. Baseline SBP 140 mm Hg Baseline SBP > 140 mm Hg (n = 1591) (n = 1632) (n = 631) (n = 662) Age, median (range), years 59 (21 86) 58 (20 84) 62 (29 84) 62 (30 81) Gender, male, n (%) 936 (58.8) 911 (55.8) 364 (57.7) 411 (62.1) Weight, mean (SD), kg 88.9 (19.3) 89.3 (20.0) 93.1 (19.0) 93.4 (19.0) Body mass index, mean (SD), kg/m (5.8) 31.9 (5.7) 33.1 (5.6) 32.9 (5.5) Duration of type 2 diabetes, mean (SD), 8.3 (7.7) 8.3 (7.7) 10.5 (8.3) 10.8 (8.5) years Baseline SBP, mean (SD), mm Hg (10.5) (10.8) (7.4) (7.8) Baseline DBP, mean (SD), mm Hg 76.3 (8.2) 76.4 (8.3) 84.2 (8.5) 83.5 (9.1) egfr, mean (SD), ml/ml/1.73 m (20.4) 83.8 (20.3) 80.3 (18.8) 80.1 (20.0) <30 ml/ml/1.73 m 2 1 (0.1) 1 (0.1) <60 ml/ml/1.73 m 2, n (%) 191 (12.0) 170 (10.4) 72 (11.4) 92 (13.9) 60 <90 ml/ml/1.73 m 2, n (%) 865 (54.4) 876 (53.7) 370 (58.6) 382 (57.7) 90 ml/ml/1.73 m 2, n (%) 533 (33.5) 585 (35.8) 189 (30.0) 188 (28.4) Unknown 1 (0.1) HbA 1c, mean (SD), % 8.1 (0.9) 8.2 (1.0) 8.3 (0.9) 8.2 (0.9) Prior history of CVD, n (%) 781 (49.1) 774 (47.4) 399 (63.2) 436 (65.9) Prior history of CHF, n (%) 92 (5.8) 101 (6.2) 53 (8.4) 66 (10.0) Prior history of hypertension, n (%) 1160 (72.9) 1126 (69.0) 585 (92.7) 610 (92.1) CHF: congestive heart failure; CVD: cardiovascular disease; DBP: diastolic blood pressure; egfr: estimated glomerular filtration rate; HbA1c: glycosylated haemoglobin; SBP: systolic blood pressure; SD: standard deviation. Table 2. Anti-hypertensive medication use at baseline and week 24 in hypertensive versus non-hypertensive patients with type 2 diabetes mellitus. Baseline SBP 140 mm Hg Baseline SBP > 140 mm Hg (n = 1591) (n = 1632) (n = 631) (n = 662) Baseline Week 24 Baseline Week 24 Baseline Week 24 Baseline Week 24 Any anti-hypertensive 1155 (72.6) 1167 (73.4) 1113 (68.2) 1123 (68.8) 575 (91.1) 581 (92.1) 606 (91.5) 612 (92.4) drugs, n (%) Diuretics 484 (30.4) 496 (31.2) 504 (30.9) 502 (30.8) 311 (49.3) 324 (51.3) 303 (45.8) 317 (47.9) Loop diuretics 139 (8.7) 146 (9.2) 132 (8.1) 133 (8.1) 69 (10.9) 79 (12.5) 71 (10.7) 73 (11.0) Thiazides 246 (15.5) 251 (15.8) 276 (16.9) 276 (16.9) 172 (27.3) 183 (29.0) 159 (24.0) 165 (24.9) Beta blocking agents 597 (37.5) 600 (37.7) 584 (35.8) 587 (36.0) 313 (49.6) 323 (51.2) 356 (53.8) 366 (55.3) Calcium channel 312 (19.6) 327 (20.6) 329 (20.2) 325 (19.9) 230 (36.5) 244 (38.7) 235 (35.5) 242 (36.6) blockers ACE inhibitors or angiotensin receptor blockers 970 (61.0) 983 (61.8) 945 (57.9) 957 (58.6) 504 (79.9) 512 (81.1) 523 (79.0) 536 (81.0) ACE: angiotensin-converting enzyme; SBP: systolic blood pressure. week 24 (Figure 2(a)). SBP in hypertensive patients treated with dapagliflozin dropped to a greater extent and remained below that of the placebo group throughout the entire study period: adjusted mean placebo-subtracted change [95% confidence interval (CI)] in SBP from baseline to week 24 was 3.6 mm Hg ( 4.9 to 2.4 mm Hg). In non-hypertensive patients, SBP remained relatively constant over time with dapagliflozin, while SBP increased with placebo over the same time period (Figure 2(b)). The adjusted mean placebosubtracted change (95% CI) in SBP from baseline to week 24 with dapagliflozin was 2.6 mm Hg ( 3.4 to 1.8 mm Hg) in non-hypertensive patients. A similar pattern in DBP was observed over time. In hypertensive patients, DBP dropped in both treatment groups over the first week, remaining comparatively constant thereafter until week 24 (Figure 3(a)). Patients treated
4 Sjöström et al. 355 Mean SBP (mmhg) BL SBP mmhg Mean SBP (mmhg) (a) BL SBP mmhg BL, baseline. (b) Figure 2. Change in systolic blood pressure (SBP) over time in patients with baseline SBP (a) >140 mm Hg or (b) 140 mm Hg. BL: baseline; DAPA: dapagliflozin; : placebo. Error bars represent 95% confidence intervals. Mean DBP (mmhg) Mean DBP (mmhg) (a) (b) with dapagliflozin showed a greater decrease from baseline in DBP; the placebo-corrected change in DBP from baseline to week 24 was 1.2 mm Hg ( 2.0 to 0.4 mm Hg). In non-hypertensive patients, little change from baseline in DBP was observed over time in the dapagliflozin group, compared with a slight increase in the placebo group [placebo-corrected change from baseline to week 24, 1.2 mm Hg ( 1.8 to 0.7 mm Hg)] (Figure 3(b)). Heart rate No clinically relevant change from baseline in heart rate was observed in either dapagliflozin- or placebo-treated patients (Figure 4). In hypertensive patients, the mean change from baseline to week 24 was 0.5 and 0.4 beats/ min, respectively, in dapagliflozin- and placebo-treated patients and was 0.1 and 0.7 beats/min, respectively, in non-hypertensive patients. Orthostatic hypotension The proportion of dapagliflozin-treated patients with any measured postural orthostatic reaction over the 24-week Figure 3. Change in diastolic blood pressure (DBP) over time in patients with baseline systolic blood pressure (SBP) (a) >140 mm Hg or (b) 140 mm Hg. BL: baseline; DAPA: dapagliflozin; : placebo. Error bars represent 95% confidence intervals. treatment period was similar to placebo in hypertensive patients (dapagliflozin, 17.4%; placebo, 15.5%). Similarly, although the frequency of orthostatic reactions over the 24-week period was lower in non-hypertensive patients, the proportion of patients with postural orthostatic hypertension was also similar between the treatment groups (dapagliflozin, 11.4%; placebo, 9.6%). At the 24-week visit, the difference was small between dapagliflozin and placebo in the proportion of patients with measured orthostatic reactions in either hypertensive (6.1% vs 6.6%) or non-hypertensive (4.0% vs 4.2%) patients, respectively (Figure 5). Adverse events falling under the MedDRA preferred term orthostatic hypotension were rare, and none were classified as serious. The highest rate was observed in the non-hypertensive placebo group (0.4%), and lower rates were observed in the non-hypertensive dapagliflozin group (0.1%) and both of the hypertensive groups (dapagliflozin, 0.2%; placebo 0%).
5 356 Diabetes & Vascular Disease Research 12(5) Heart rate (bpm) Heart rate (bpm) Error barsrepresent 95% CI. (a) (b) Figure 4. Change in heart rate in patients with baseline systolic blood pressure (SBP) (a) >140 mm Hg or (b) 140 mm Hg. BL: baseline; bpm: beats per minute; DAPA: dapagliflozin; : placebo. Proportion of patients with measured orthostatic reactions (%) SBP 140 mmhg SBP 140 mmhg DAPA SBP > 140 mmhg SBP > 140 mmhg DAPA Figure 5. Measured orthostatic reactions. DAPA: dapagliflozin; : placebo; SBP: systolic blood pressure. 24 Patients with SBP 120 mm Hg An additional subgroup analysis of the non-hypertensive patients described above was performed in 1081 patients with SBP 120 mm Hg. In the dapagliflozin group, 566 patients had a baseline SBP 120 mm Hg, and the corresponding number for placebo was 515 patients. The mean [standard deviation (SD)] SBP was mm Hg (6.5 mm Hg) and mm Hg (6.9 mm Hg) for dapagliflozin and placebo, respectively. SBP values ranged from 81.7 to 120 mm Hg. The corresponding values for DBP were 71.9 mm Hg (7.1 mm Hg) and 71.7 mm Hg (7.7 mm Hg), respectively. The adjusted mean placebo-subtracted change (95% CI) in SBP from baseline to week 24 with dapagliflozin was 2.5 mm Hg ( 3.9 to 1.1 mm Hg) and for DBP was 1.7 mm Hg ( 2.6 to 0.9 mm Hg). Heart rate increased on average 0.7 beats/min in the dapagliflozin group and 1.4 beats/min in the placebo group. The proportion of dapagliflozin-treated patients with any measured postural orthostatic reaction over the 24-week treatment period was similar to placebo (dapagliflozin, 9.9%; placebo, 8.7%). The corresponding proportion of patients with a measured postural orthostatic reaction at the 24-week visit was 3.8% and 2.6%, respectively. There were no registered adverse events of orthostatic hypertension among the dapagliflozin-treated patients with a baseline SBP 120 mm Hg. Discussion These analyses were performed to evaluate whether baseline BP prior to initiating dapagliflozin would have any impact on the subsequent BP-lowering effect of dapagliflozin in patients with T2DM. A safety analysis was also performed to evaluate possible differential effects on heart rate and orthostatic reactions in hypertensive and nonhypertensive patients. To our knowledge, this is the first analysis evaluating the impact of pre-treatment BP on the BP-lowering effect observed with an SGLT2 inhibitor in patients with T2DM. Oral dapagliflozin 10 mg/day, administered as monotherapy or add-on to existing anti-hyperglycaemic agents, induced a modest reduction in BP versus placebo over the first week of treatment that persisted thereafter, regardless of baseline BP category. The apparently larger absolute reductions from baseline observed in hypertensive versus non-hypertensive patients, independent of treatment assignment, are most likely an effect of regression to the mean. This would be expected after an arbitrary dichotomisation of a study cohort with patients above the cut-off level showing reduced repeat values and those below showing a tendency toward increased values over time. We do not believe that this would compromise the main findings, as both placebo- and dapagliflozin-treated patients would be affected equally. Taking this into account, the most appropriate comparison under such circumstances
6 Sjöström et al. 357 was to use the placebo-corrected values to compare effects in hypertensive and non-hypertensive patients. A slightly higher proportion of patients (~2%) receiving dapagliflozin compared with placebo experienced any measured orthostatic reaction over the entire 24-week observation period. This difference from placebo seemed independent of baseline BP category. Overall, hypertensive patients displayed a higher frequency of orthostatic reactions as compared with those with lower baseline BP, independent of the treatment assignment. This may be due to the more frequent use of anti-hypertensive medications by hypertensive patients as well as more adverse cardiovascular status such as arterial stiffness and compromised compensatory mechanisms. Also, the definition of measured orthostatic reactions might lead to more patients with high SBP fulfilling the criteria for an event. It was, therefore, reassuring that the number of clinically registered adverse events of orthostatic hypotension was not increased in the dapagliflozin group as compared with placebo. No clinically relevant change from baseline in heart rate was observed in either dapagliflozin- or placebo-treated patients. The main findings of this investigation were corroborated in a sensitivity analysis comprising only those patients with SBP 120 mm Hg. In this cohort, dapagliflozin induced a modest reduction in BP similar in magnitude to the cohorts with higher baseline BP, without a substantial increase in orthostatic reactions as compared with placebo. A limitation when interpreting these results is that the change in BP was not defined as the primary study objective in most of the studies pooled for this analysis. As such, the control, or monitoring of BP medication changes, was suboptimal, making it not possible to control for possible changes in dosage, even though the number of patients on anti-hypertensive medications across the trials was known. However, given the stable number of patients using different types of anti-hypertensives over the 24-week period, it is unlikely that the observed placebo-corrected reductions in BP levels are explained by dose adjustments. These results accumulated from placebo-controlled studies across the dapagliflozin clinical programme indicate a lowering of SBP regardless of baseline BP category not accompanied by orthostatic hypotension. These data may provide guidance for physicians when prescribing dapagliflozin, particularly in patients on concomitant anti-hypertensive medications who could benefit from additional glycaemic, weight and BP control. The long-term clinical benefits of dapagliflozin treatment were not studied here but are currently under investigation in a large-scale outcome study (DECLARE, NCT clinicaltrials.gov). Declaration of conflicting interests C. David Sjöström, Peter Johansson and Eva Johnsson are employees and shareholders of AstraZeneca. Agata Ptaszynska is an employee and shareholder of Bristol-Myers Squibb. James List was an employee and shareholder of Bristol-Myers Squibb at the time the analysis was conducted. Funding This analysis was funded by AstraZeneca. Editorial support was provided by Karen Pemberton, PhD, of PPSI (a PAREXEL company) and was funded by AstraZeneca. References 1. Sowers JR, Epstein M and Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001; 37: Davis TM, Millns H, Stratton IM, et al. Risk factors for stroke in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 29. Arch Intern Med 1999; 159: Hu G, Sarti C, Jousilahti P, et al. The impact of history of hypertension and type 2 diabetes at baseline on the incidence of stroke and stroke mortality. Stroke 2005; 36: Obesity and Overweight. World Health Organization: global strategy on diet, physical activity and health, 2003, pdf 5. Borne AT, Truett AA, Monteiro MP, et al. Changes in skeletal muscle vascular resistance with weight gain: associations with insulin and sympathetic activity. Obes Res 1999; 7: Hsueh WA and Wyne K. Renin-angiotensin-aldosterone system in diabetes and hypertension. J Clin Hypertens (Greenwich) 2011; 13: Manrique C, Lastra G, Gardner M, et al. The renin angiotensin aldosterone system in hypertension: roles of insulin resistance and oxidative stress. Med Clin North Am 2009; 93: Brands MW and Manhiani MM. Sodium-retaining effect of insulin in diabetes. Am J Physiol Regul Integr Comp Physiol 2012; 303: R1101 R Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998; 317: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317: Mancia G, Fagard R, Narkiewicz K, et al ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: Standards of medical care in diabetes Diabetes Care 2014; 37(Suppl. 1): S14 S Paneni F ESC/EASD guidelines on the management of diabetes and cardiovascular disease: established knowledge and evidence gaps. Diab Vasc Dis Res 2014; 11: Law MR, Morris JK and Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b List JF, Woo V, Morales E, et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009; 32:
7 358 Diabetes & Vascular Disease Research 12(5) 16. Bailey CJ, Gross JL, Hennicken D, et al. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med 2013; 11: Ferrannini E, Ramos SJ, Salsali A, et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010; 33: Nauck MA, Del Prato S, Duran-Garcia S, et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes Obes Metab 2014; 16: Strojek K, Yoon KH, Hruba V, et al. Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebo-controlled trial. Diabetes Ther 2014; 5: Lambers Heerspink HJ, de Zeeuw D, Wie L, et al. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 2013; 15: Sjostrom CD, Hashemi M, Sugg J, et al. Dapagliflozininduced weight loss impacts 24 week HbA1c and blood pressure levels. Diabetolgia 2013; 56: S Dornfeld LP, Maxwell MH, Waks AU, et al. Obesity and hypertension: long-term effects of weight reduction on blood pressure. Int J Obes 1985; 9: Sjostrom CD, Peltonen M and Sjostrom L. Blood pressure and pulse pressure during long-term weight loss in the obese: the Swedish Obese Subjects (SOS) Intervention Study. Obes Res 2001; 9:
Study Design: Prospective, Multicenter randomized, parallel-group, double blind, placebo controlled study.
Brand Name: Farxiga Generic Name: Dapagliflozin Manufacturer: Astra-Zenica Drug Class 1,2 : Antidiabetic agent, SGLT2 Inhibitor Uses: Labeled Uses 1,2,3,4 : Improving glycemic control in adults with type
More informationThe Journal of Clinical Hypertension Vol 16 No 12 December
ORIGINAL PAPER Effect of Canagliflozin on Blood Pressure and Adverse Events Related to Osmotic Diuresis and Reduced Intravascular Volume in Patients With Type 2 Diabetes Mellitus Matthew R. Weir, MD; 1
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Dapagliflozin in combination therapy for the Final scope Remit/appraisal objective To appraise the clinical and
More informationSoo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital
Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital Agenda Association between Cardiovascular Disease and Type 2 Diabetes Importance of HbA1c Management esp. High risk patients
More informationStudy Duration (Weeks) Reference Number
Supplementary Table 1. SGLT2 Inhibitor Monotherapy SGLT2 Inhibitor vs /Comparator Canagliflozin 100 mg Canagliflozin 300 mg 26 26 (n) 195 197 in 0.91 1.16 in FPG 36.0 43.2 Canagliflozin 100 mg Canagliflozin
More informationThe promise of the thiazolidinediones in the management of type 2 diabetes-associated cardiovascular disease
The promise of the thiazolidinediones in the management of type 2 diabetes-associated cardiovascular disease Steve Smith, Group Director Scientific Affairs, Diabetes & Metabolism GlaxoSmithKline R & D
More informationBrand Name: Farxiga. Generic Name: dapagliflozin. Manufacturer 1 : Bristol-Myers Squibb
Brand Name: Farxiga Generic Name: dapagliflozin Manufacturer 1 : Bristol-Myers Squibb Drug Class 1,3,4 : Antidiabetic, sodium-glucose cotransporter 2 (SGLT2) inhibitor Uses Labeled Uses 1,2,3,4,5 : Adjunct
More informationABSTRACT ORIGINAL RESEARCH. John Wilding. Clifford Bailey. Una Rigney. Betina Blak. Wendy Beekman. Cathy Emmas
Diabetes Ther (2016) 7:695 711 DOI 10.1007/s13300-016-0193-8 ORIGINAL RESEARCH Glycated Hemoglobin, Body Weight and Blood Pressure in Type 2 Diabetes Patients Initiating Dapagliflozin Treatment in Primary
More informationDysglycaemia and Hypertension. Dr E M Manuthu Physician Kitale
Dysglycaemia and Hypertension Dr E M Manuthu Physician Kitale None Disclosures DM is MI equivalent MR FIT Objective was to assess predictors of CVD mortality among men with and without diabetes and
More informationdapagliflozin 5mg and 10mg film-coated tablets (Forxiga ) SMC No. (799/12) Bristol-Myers Squibb / AstraZeneca
dapagliflozin 5mg and 10mg film-coated tablets (Forxiga ) SMC No. (799/12) Bristol-Myers Squibb / AstraZeneca 07 September 2012 (Issued 07 December 2012) The Scottish Medicines Consortium (SMC) has completed
More informationWhich antihypertensives are more effective in reducing diastolic hypertension versus systolic hypertension? May 24, 2017
Which antihypertensives are more effective in reducing diastolic hypertension versus systolic hypertension? May 24, 2017 The most important reason for treating hypertension in primary care is to prevent
More informationBrand name: Steglatro. Generic name: Ertugliflozin (er too gli FLOE zin) Manufacturer: Merck
Brand name: Steglatro Generic name: Ertugliflozin (er too gli FLOE zin) Manufacturer: Merck Drug Class: Sodium-glucose co-transporter 2 (SGLT2) inhibitor Uses: Labeled: Indicated as adjunct to diet and
More informationSGLT2 inhibition in diabetes: extending from glycaemic control to renal and cardiovascular protection
SGLT2 inhibition in diabetes: extending from glycaemic control to renal and cardiovascular protection Hiddo Lambers Heerspink Department of Clinical Pharmacy and Pharmacology University Medical Center
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More informationCedars Sinai Diabetes. Michael A. Weber
Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor
More informationA fixed-dose combination of bisoprolol and amlodipine in daily practice treatment of hypertension: Results of a noninvestigational
Hostalek U et al. Medical Research Archives, vol. 5, issue 11, November 2017 issue Page 1 of 11 RESEARCH ARTICLE A fixed-dose combination of bisoprolol and amlodipine in daily practice treatment of hypertension:
More informationCase study: Lean adult with no complications, newly diagnosed with type 2 diabetes
Case study: Lean adult with no complications, newly diagnosed with type 2 diabetes Authored by Clifford Bailey and James LaSalle on behalf of the Global Partnership for Effective Diabetes Management. The
More informationSGLT2 Inhibitors
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.07.19 Subject: SGLT2 Inhibitors Page: 1 of 5 Last Review Date: December 3, 2015 SGLT2 Inhibitors Description
More informationGlucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetes
575273TAE0010.1177/2042018815575273Therapeutic Advances in Endocrinology and MetabolismD Hinnen research-article2015 Therapeutic Advances in Endocrinology and Metabolism Review Glucuretic effects and renal
More informationVariability in drug response: towards more personalized diabetes care Petrykiv, Sergei
University of Groningen Variability in drug response: towards more personalized diabetes care Petrykiv, Sergei IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you
More informationCombination Therapy for Hypertension
Combination Therapy for Hypertension Se-Joong Rim, MD Cardiology Division, Yonsei University College of Medicine, Seoul, Korea Goals of Therapy Reduce CVD and renal morbidity and mortality. Treat to BP
More informationEfficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials
Diabetes, Obesity and Metabolism 2013. 2013 John Wiley & Sons Ltd Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials M. Monami
More informationDiabetes and Hypertension
Diabetes and Hypertension M.Nakhjvani,M.D Tehran University of Medical Sciences 20-8-96 Hypertension Common DM comorbidity Prevalence depends on diabetes type, age, BMI, ethnicity Major risk factor for
More informationNon-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
More informationSCIENTIFIC STUDY REPORT
PAGE 1 18-NOV-2016 SCIENTIFIC STUDY REPORT Study Title: Real-Life Effectiveness and Care Patterns of Diabetes Management The RECAP-DM Study 1 EXECUTIVE SUMMARY Introduction: Despite the well-established
More informationWhy is Earlier and More Aggressive Treatment of T2 Diabetes Better?
Blood glucose (mmol/l) Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Disclosures Dr Kennedy has provided CME, been on advisory boards or received travel or conference support from:
More informationDISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE
ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE DISCLOSURES Editor-in-Chief- Nephrology- UpToDate- (Wolters Klewer) Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA 1 st Annual Internal
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal Canagliflozin in combination therapy for Final scope Remit/appraisal objective To appraise the clinical and cost effectiveness
More informationThe problem of uncontrolled hypertension
(2002) 16, S3 S8 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh The problem of uncontrolled hypertension Department of Public Health and Clinical Medicine, Norrlands
More information740 Diabetes Care Volume 37, March 2014
740 Diabetes Care Volume 37, March 2014 Is Effective as Add-on Therapy to Sitagliptin With or Without Metformin: A 24-Week, Multicenter, Randomized, Double-Blind, -Controlled Study Serge A. Jabbour, 1
More informationSGLT2 Inhibition in the Management of T2DM: Potential Impact on CVD Risk
Managing Diabetes & CVD: Expling New Evidence & Opptunities ESC Congress, London, UK 30 August, 2015 SGLT2 Inhibition in the Management of T2DM: Potential Impact on CVD Risk Silvio E. Inzucchi MD Yale
More informationEffect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis
Diabetes Ther (2016) 7:125 137 DOI 10.1007/s13300-015-0150-y ORIGINAL RESEARCH Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis
More informationSESSION 4 12:30pm 1:45pm
SESSION 4 12:30pm 1:45pm Addressing Renal-Mediated Glucose Homeostasis: Diabetes and the Kidney SPEAKER Davida Kruger, MSN, BC-ADM, APRN Presenter Disclosure Information The following relationships exist
More informationSlide notes: References:
1 2 3 Cut-off values for the definition of hypertension are systolic blood pressure (SBP) 135 and/or diastolic blood pressure (DBP) 85 mmhg for home blood pressure monitoring (HBPM) and daytime ambulatory
More informationBristol-Myers Squibb / AstraZeneca ADVICE dapagliflozin (Forxiga ) Indication under review: SMC restriction: Chairman, Scottish Medicines Consortium
Re-Submission dapagliflozin 5mg and 10mg film-coated tablets (Forxiga ) SMC No. (799/12) Bristol-Myers Squibb / AstraZeneca 07 February 2014 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationCanagliflozin in combination therapy for treating type 2 diabetes
Canagliflozin in combination therapy for treating type 2 Issued: June 2014 guidance.nice.org.uk/ta NICE has accredited the process used by the Centre for Health Technology Evaluation at NICE to produce
More informationMetformin should be considered in all patients with type 2 diabetes unless contra-indicated
November 2001 N P S National Prescribing Service Limited PPR fifteen Prescribing Practice Review PPR Managing type 2 diabetes For General Practice Key messages Metformin should be considered in all patients
More informationThe ABCs (A1C, BP and Cholesterol) of Diabetes
The ABCs (A1C, BP and Cholesterol) of Diabetes Gregg Simonson, PhD Director, Professional Training and Consulting International Diabetes Center; Adjunct Assistant Professor, University of Minnesota Department
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationADVANCE post trial ObservatioNal Study
Hot Topics in Diabetes 50 th EASD, Vienna 2014 ADVANCE post trial ObservatioNal Study Sophia Zoungas The George Institute The University of Sydney Rationale and Study Design Sophia Zoungas The George Institute
More informationHypertension Update Clinical Controversies Regarding Age and Race
Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT
More informationSMJ Singapore Medical Journal
SMJ Singapore Medical Journal ONLINE FIRST PUBLICATION Online first papers have undergone full scientific review and copyediting, but have not been typeset or proofread. To cite this article, use the DOIs
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationROLE OF KIDNEY AND SGLT-2 INHIBITOR IN GLUCOSE HOMEOSTASIS
ROLE OF KIDNEY AND SGLT-2 INHIBITOR IN GLUCOSE HOMEOSTASIS Prof. Dato Dr. Mafauzy Mohamed Professor of Medicine / Senior Consultant Endocrinologist Health Campus, UniversiB Sains Malaysia The Kidneys Maintain
More informationSGLT2 Inhibitors
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.19 Subject: SGLT2 Inhibitors Page: 1 of 6 Last Review Date: September 15, 2016 SGLT2 Inhibitors Description
More informationJNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
More informationHypertension and obesity. Dr Wilson Sugut Moi teaching and referral hospital
Hypertension and obesity Dr Wilson Sugut Moi teaching and referral hospital No conflict of interests to declare Obesity Definition: excessive weight that may impair health BMI Categories Underweight BMI
More informationReframe the Paradigm of Hypertension treatment Focus on Diabetes
Reframe the Paradigm of Hypertension treatment Focus on Diabetes Paola Atallah, MD Lecturer of Clinical Medicine SGUMC EDL monthly meeting October 25,2016 Overview Physiopathology of hypertension Classification
More informationMetabolic Syndrome and Chronic Kidney Disease
Metabolic Syndrome and Chronic Kidney Disease Definition of Metabolic Syndrome National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Abdominal obesity, defined as a waist circumference
More informationClinical Relevance of Blood Pressure Lowering Effect of Modern Antidiabetic Drugs
Clinical Relevance of Blood Pressure Lowering Effect of Modern Antidiabetic Drugs Professor Guntram Schernthaner Medical University of Vienna, Austria guntram.schernthaner@meduniwien.ac.at Agenda Glucose
More informationNew Antihypertensive Strategies to Improve Blood Pressure Control
New Antihypertensive Strategies to Improve Blood Pressure Control Antonio Coca, MD, PhD,, FRCP, FESC Hypertension and Vascular Risk Unit Department of Internal Medicine. Hospital Clínic (IDIBAPS) University
More informationNo Increased Cardiovascular Risk for Lixisenatide in ELIXA
ON ISSUES IN THE MANAGEMENT OF TYPE 2 DIABETES JUNE 2015 Coverage of data from ADA 2015, June 5 9 in Boston, Massachusetts No Increased Cardiovascular Risk for Lixisenatide in ELIXA First Cardiovascular
More informationDapagliflozin and cardiovascular outcomes in type 2
EARN 3 FREE CPD POINTS diabetes Leader in digital CPD for Southern African healthcare professionals Dapagliflozin and cardiovascular outcomes in type 2 diabetes Introduction People with type 2 diabetes
More informationOnline Appendix (JACC )
Beta blockers in Heart Failure Collaborative Group Online Appendix (JACC013117-0413) Heart rate, heart rhythm and prognostic effect of beta-blockers in heart failure: individual-patient data meta-analysis
More informationEfficacy of Body Weight Reduction on the SGLT2 Inhibitor in People with Type 2 Diabetes Mellitus
Journal of Obesity & Metabolic Syndrome 2017;26:107-113 Original Article pissn 2508-6235 eissn 2508-7576 Efficacy of Body Weight Reduction on the SGLT2 Inhibitor in People with Type 2 Diabetes Mellitus
More informationDrug Class Monograph
Drug Class Monograph Class: Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drugs: Farxiga (dapagliflozin), Invokamet (canagliflozin/metformin), Invokana (canagliflozin), Jardiance (empagliflozin),
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. ACE Inhibitor and Angiotensin II Antagonist Combination Treatment GUIDELINES
ACE Inhibitor and Angiotensin II Antagonist Combination Treatment Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES No recommendations possible based on Level
More informationManaging HTN in the Elderly: How Low to Go
Managing HTN in the Elderly: How Low to Go Laxmi S. Mehta, MD, FACC The Ohio State University Medical Center Assistant Professor of Clinical Internal Medicine Clinical Director of the Women s Cardiovascular
More informationThe role of physical activity in the prevention and management of hypertension and obesity
The 1 st World Congress on Controversies in Obesity, Diabetes and Hypertension (CODHy) Berlin, October 26-29 2005 The role of physical activity in the prevention and management of hypertension and obesity
More informationPrevention And Treatment of Diabetic Nephropathy. MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan
Prevention And Treatment of Diabetic Nephropathy MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan Prevention Tight glucose control reduces the development of diabetic nephropathy Progression
More informationMultiple Factors Should Be Considered When Setting a Glycemic Goal
Multiple Facts Should Be Considered When Setting a Glycemic Goal Patient attitude and expected treatment effts Risks potentially associated with hypoglycemia, other adverse events Disease duration Me stringent
More informationType 2 diabetes (T2D) affected approximately 30.3 million
REPORT A Retrospective Real-World Study of Dapagliflozin Versus Other Oral Antidiabetic Drugs Added to Metformin in Patients with Type 2 Diabetes Huan Huang, PhD; Kelly F. Bell, PharmD, MSPhr; Ray Gani,
More informationLong-Term Care Updates
Long-Term Care Updates August 2015 By Darren Hein, PharmD Hypertension is a clinical condition in which the force of blood pushing on the arteries is higher than normal. This increases the risk for heart
More informationNOTICE. Release of final Health Canada document: Standards for Clinical Trials in Type 2 Diabetes in Canada
September 24, 2007 NOTICE Our file number: 07-122151-509 Release of final Health Canada document: Standards for Clinical Trials in Type 2 Diabetes in Canada The final version of the Health Canada guidance
More informationSodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol
Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has
More informationSGLT2 Inhibitors
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: SGLT2 Inhibitors Page: 1 of 7 Last Review Date: June 22, 2018 SGLT2 Inhibitors Description Invokana
More informationDapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving reninangiotensin
University of Groningen Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving reninangiotensin blockers Heerspink, H. J. L.; Johnsson, E.; Gause-Nilsson, I.; Cain, V. A.;
More informationDiabete: terapia nei pazienti a rischio cardiovascolare
Diabete: terapia nei pazienti a rischio cardiovascolare Giorgio Sesti Università Magna Graecia di Catanzaro Cardiovascular mortality in relation to diabetes mellitus and a prior MI: A Danish Population
More informationDiabetes and New Meds for Cardiovascular Risk Reduction. F. Dwight Chrisman, MD, FACC. Disclosures: BI Boehringer Ingelheim speaker
Diabetes and New Meds for Cardiovascular Risk Reduction F. Dwight Chrisman, MD, FACC Disclosures: BI Boehringer Ingelheim speaker 1 Prevalence of DM DM state specific prevalence 2006 4%-6% 6-8% 8-10% 10-12%
More informationABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour
ABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour Dr Indranil Dasgupta Rationale No national practical
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Dapagliflozin for the treatment of type 2 diabetes
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Dapagliflozin for the treatment of type 2 diabetes Submitted by Bristol-Myers Squibb and AstraZeneca Single technology appraisal (STA) 17 th July 2012
More informationempagliflozin 10mg and 25mg tablet (Jardiance ) SMC No. (993/14) Boehringer Ingelheim / Eli Lilly
empagliflozin 10mg and 25mg tablet (Jardiance ) SMC No. (993/14) Boehringer Ingelheim / Eli Lilly 05 September 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationIDF Regions and global projections of the number of people with diabetes (20-79 years), 2013 and Diabetes Atlas -sixth Edition: IDF 2013
IDF Regions and global projections of the number of people with diabetes (20-79 years), 2013 and 2035 Diabetes Atlas -sixth Edition: IDF 2013 Diabetes Atlas -sixth Edition: IDF 2013 Chronic complications
More informationThe EMPA-REG OUTCOME trial: Design and results. David Fitchett, MD University of Toronto, Canada
The EMPA-REG OUTCOME trial: Design and results David Fitchett, MD University of Toronto, Canada Asian Cardio Diabetes Forum April 23 24, 2016 Kuala Lumpur, Malaysia Life Expectancy Is Reduced by ~12 Years
More informationThe retinal renin-angiotensin system: implications for therapy in diabetic retinopathy
(2002) 16, S42 S46 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh : implications for therapy in diabetic retinopathy AK Sjølie 1 and N Chaturvedi 2 1 Department
More informationSGLT2 inhibition with dapagliflozin
Gary Kilov Stephen Leow Merlin Thomas SGLT2 inhibition with dapagliflozin A novel approach for the management of type 2 diabetes Background Because of the progressive nature of the disease, most patients
More informationJARDIAMET. (empagliflozin and metformin hydrochloride) 5 mg/500 mg, 5 mg/850 mg, 5 mg/1000 mg, 12.5 mg/500 mg, 12.5 mg/850 mg, 12.
JARDIAMET (empagliflozin and metformin hydrochloride) 5 mg/500 mg, 5 mg/850 mg, 5 mg/1000 mg, 12.5 mg/500 mg, 12.5 mg/850 mg, 12.5 mg/1000 mg NAME OF THE MEDICINE JARDIAMET contains two oral antihyperglycaemic
More informationΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH
ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH Hypertension Co-Morbidities HTN Commonly Clusters with Other Risk
More informationEfficacy and Safety of SGLT2 Inhibitors in Reducing Glycated Hemoglobin and Weight in Emirati Patients With Type 2 Diabetes
Elmer ress Original Article J Clin Med Res. 2017;9(6):499-507 Efficacy and Safety of SGLT2 Inhibitors in Reducing Glycated Hemoglobin and Weight in Emirati Patients With Type 2 Diabetes Alaaeldin Bashier
More informationSummary of recommendations
Summary of recommendations Measuring blood pressure (BP) Use the recommended technique at every BP reading to ensure accurate measurements and avoid common errs. Pay particular attention to the following:
More informationEmpagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus
Diabetes Ther (2017) 8:33 53 DOI 10.1007/s13300-016-0211-x REVIEW Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus John E. Anderson. Eugene E. Wright Jr.. Charles F.
More informationMetoprolol Succinate SelokenZOC
Metoprolol Succinate SelokenZOC Blood Pressure Control and Far Beyond Mohamed Abdel Ghany World Health Organization - Noncommunicable Diseases (NCD) Country Profiles, 2014. 1 Death Rates From Ischemic
More informationSafety profile of Liraglutide: Recent Updates. Mohammadreza Rostamzadeh,M.D.
Safety profile of Liraglutide: Recent Updates Mohammadreza Rostamzadeh,M.D. Pancreatitis: Victoza post-marketing experience: spontaneous reports of pancreatitis For the majority of the cases, there is
More informationStages of Chronic Kidney Disease (CKD)
Early Treatment is the Key Stages of Chronic Kidney Disease (CKD) Stage Description GFR (ml/min/1.73 m 2 ) >90 1 Kidney damage with normal or GFR 2 Mild decrease in GFR 60-89 3 Moderate decrease in GFR
More informationEarly treatment for patients with Type 2 Diabetes
Israel Society of Internal Medicine Kibutz Hagoshrim, June 22, 2012 Early treatment for patients with Type 2 Diabetes Eduard Montanya Hospital Universitari Bellvitge-IDIBELL CIBERDEM University of Barcelona
More information01/09/2017. Outline. SGLT 2 inhibitor? Diabetes Patients: Complex and Heterogeneous. Association between diabetes and cardiovascular events
MICROVASCULAR COMPLICATIONS Incidence of outcome g 1 Cardioprotective Effects of SGLT2s Relevant for Which T2 Diabetes Patient? SGLT 2 inhibitor? 58 year old, waist circumference 5 cm, PMH: IHD On statin,
More informationDiabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of
More informationNational Institute for Health and Care Excellence. Single Technology Appraisal (STA) Empagliflozin combination therapy for treating type 2 diabetes
National Institute for Health and Care Excellence Comment 1: the draft remit Single Technology Appraisal (STA) Empagliflozin combination therapy for treating type 2 diabetes Response to consultee and commentator
More informationFirst line treatment of primary hypertension
First line treatment of primary hypertension Dr. Vijaya Musini Assistant Professor, Dept. Anesthesiology, Pharmacology and Therapeutics Manager, Drug Assessment Working Group Therapeutics Initiative Editor,
More informationHypertension and Cardiovascular Disease
Hypertension and Cardiovascular Disease Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic,
More informationUsing the New Hypertension Guidelines
Using the New Hypertension Guidelines Kamal Henderson, MD Department of Cardiology, Preventive Medicine, University of North Carolina School of Medicine Kotchen TA. Historical trends and milestones in
More informationInitiating Insulin in Primary Care for Type 2 Diabetes Mellitus. Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre
Initiating Insulin in Primary Care for Type 2 Diabetes Mellitus Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre Outline How big is the problem? Natural progression of type 2 diabetes What
More informationHypertension Management Controversies in the Elderly Patient
Hypertension Management Controversies in the Elderly Patient Juan Bowen, MD Geriatric Update for the Primary Care Provider November 17, 2016 2016 MFMER slide-1 Disclosure No financial relationships No
More informationManaging patients with renal disease
Managing patients with renal disease Hiddo Lambers Heerspink, MD University Medical Centre Groningen, The Netherlands Asian Cardio Diabetes Forum April 23 24, 216 Kuala Lumpur, Malaysia Prevalent cases,
More informationSitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP
Sitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP KEY POINTS sitagliptin (Januvia) is a DPP-4 inhibitor that blocks the breakdown of the
More informationTechnology appraisal guidance Published: 26 June 2013 nice.org.uk/guidance/ta288
Dapagliflozin in combination therapy for treating type 2 diabetes Technology appraisal guidance Published: 26 June 2013 nice.org.uk/guidance/ta288 NICE 2018. All rights reserved. Subject to Notice of rights
More informationInvokana (canagliflozin) NEW INDICATION REVIEW
Invokana (canagliflozin) NEW INDICATION REVIEW Introduction Brand name: Invokana Generic name: Canagliflozin Pharmacological class: Sodium-glucose cotransporter 2 (SGLT2) inhibitor Strength and Formulation:
More informationALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic
1 U.S. Department of Health and Human Services National Institutes of Health Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker
More informationTreating Hypertension in Individuals with Diabetes
Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any
More informationBy Prof. Khaled El-Rabat
What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating
More information